ORGO (Organogenesis Corp) חוב להון עצמי

Organogenesis Holdings (ORGO) operates in the resilient regenerative medicine sector, where demand remains independent of economic conditions. The financial leverage trend regarding the debt-to-equity ratio confirms this stability, and 0.22 shows the current value of the metric. Its gold-standard status in clinics guarantees physician loyalty, while the expanded distribution of new tissues drives real business growth in real-time.

This ratio determines the financial stability of the business through the balance of liabilities and equity. By analyzing the debt-to-equity ratio, an investor assesses the risk of default during external shocks. The metric is calculated as the sum of all loans divided by the company's net assets. For Organogenesis Holdings (ORGO), this level is critical, as a high debt load could limit growth if Medicare insurance reimbursement terms change.